Search - tctmd.com

Displaying 401 - 420 of 502

Sort: Relevancy | Date

News Daily News

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

L.A. McKeown

June 01, 2012

Presentation

Changes to Polymer Surface of Drug-Eluting Stents During Balloon Expansion

Presenter: 167498|Scott Denardo

May 24, 2012

News Conference News EuroPCR 2012

EuroPCR 2012: Biodegradable Devices, Imaging Take Center Stage

Caitlin E. Cox

May 22, 2012

News Conference News EuroPCR 2012

No Clear Winner in Tests Between Biodegradable-Polymer DES vs. Conventional SES

Caitlin E. Cox

May 18, 2012

News Conference News EuroPCR 2012

Trials Take on Permanent- vs. Biodegradable-Polymer Technology

Caitlin E. Cox

May 17, 2012

News Conference News EuroPCR 2012

CIBELES: Xience Stands Up to Cypher for CTO PCI

Caitlin E. Cox

May 17, 2012

News Conference News EuroPCR 2012

Strong Showing for Bioabsorbable-Scaffold DES

Caitlin E. Cox

May 16, 2012

News Daily News

Meta-Analysis: First-Gen DES Show Long-term Safety, Efficacy in STEMI Setting

L.A. McKeown

April 25, 2012

Presentation Fellows 2012

Next-Generation Technologies: Bioabsorbable Stents/Polymers, Drug-Eluting Balloons, and More

Presenter: Juan Granada

April 21, 2012

Presentation Fellows 2012

First-Generation Drug-Eluting Stents: The Good, the Bad, and the Ugly

Presenter: Issam Moussa

April 21, 2012

News Daily News

Baseline Anemia Raises Risk for Stent Thrombosis After DES

L.A. McKeown

April 04, 2012

News Conference News ACC 2012

Two Studies Highlight Safety, Efficacy of Biodegradable Polymer SES

L.A. McKeown

March 26, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Caitlin E. Cox

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

Presentation ACC 2012

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Presenter: Robert A. Byrne

March 24, 2012

Presentation PCI Outcomes 2012

Controversy 1: Current Drug-Eluting Stents Are Not Only More Effective But Are Safer Than Bare Metal Stents and Should Be Used in more than 90% of (Stented) Patients

Presenter: Gregg W. Stone

March 23, 2012

News Daily News

Celecoxib Enhances DES Efficacy, But at Clinical Cost

March 15, 2012

News Daily News

Study Finds No ‘Obesity Paradox’ in DES-Treated Patients

Jason Kahn

March 06, 2012

News Daily News

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

Yael L. Maxwell

March 06, 2012

News Daily News

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Jason Kahn

March 06, 2012

Advertisement

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

Changes to Polymer Surface of Drug-Eluting Stents During Balloon Expansion

EuroPCR 2012: Biodegradable Devices, Imaging Take Center Stage

No Clear Winner in Tests Between Biodegradable-Polymer DES vs. Conventional SES

Trials Take on Permanent- vs. Biodegradable-Polymer Technology

CIBELES: Xience Stands Up to Cypher for CTO PCI

Strong Showing for Bioabsorbable-Scaffold DES

Meta-Analysis: First-Gen DES Show Long-term Safety, Efficacy in STEMI Setting

Next-Generation Technologies: Bioabsorbable Stents/Polymers, Drug-Eluting Balloons, and More

First-Generation Drug-Eluting Stents: The Good, the Bad, and the Ugly

Baseline Anemia Raises Risk for Stent Thrombosis After DES

Two Studies Highlight Safety, Efficacy of Biodegradable Polymer SES

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Controversy 1: Current Drug-Eluting Stents Are Not Only More Effective But Are Safer Than Bare Metal Stents and Should Be Used in more than 90% of (Stented) Patients

Celecoxib Enhances DES Efficacy, But at Clinical Cost

Study Finds No ‘Obesity Paradox’ in DES-Treated Patients

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content